The prognostic significance of tumor-immune microenvironment in ascites of patients with high-grade serous carcinoma

被引:3
作者
Miceska, Simona [1 ,2 ]
Skof, Erik [2 ,3 ]
Bucek, Simon [1 ,2 ]
Kuhar, Cvetka Grasic [2 ,3 ]
Gasljevic, Gorana [4 ]
Smrkolj, Spela [2 ,5 ]
Prevodnik, Veronika Kloboves [1 ,6 ,7 ]
机构
[1] Inst Oncol Ljubljana, Dept Cytopathol, Ljubljana, Slovenia
[2] Univ Ljubljana, Fac Med, Ljubljana, Slovenia
[3] Inst Oncol Ljubljana, Dept Med Oncol, Ljubljana, Slovenia
[4] Inst Oncol Ljubljana, Dept Pathol, Ljubljana, Slovenia
[5] Univ Med Ctr, Div Gynaecol & Obstet, Ljubljana, Slovenia
[6] Univ Maribor, Fac Med, Maribor, Slovenia
[7] Dept Cytopathol, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia
关键词
ascites; immune cells; high-grade serous carcinoma; PD-1; PD-L1; prognostic markers; REGULATORY T-CELLS; INFILTRATING LYMPHOCYTES; OVARIAN-CANCER; FAVORABLE PROGNOSIS; NK-CELL; CD103; PD-1; EXPRESSION; CONTRIBUTE; SURVIVAL;
D O I
10.2478/raon-2023-0046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. High-grade serous carcinoma (HGSC) is often associated with ascites at presentation. Our objective was to quantify immune cells (ICs) in ascites prior to any treatment was given and evaluate their impact on progres-sion-free survival (PFS) and overall survival (OS). Patients and methods. Forty-seven patients with primary HGSC and ascites were included. Flow-cytometric analysis was performed to detect percentages of CD3(+) T cells (CD4(+), CD8(+), Tregs, and NKT cells), B cells, NK cells (CD56(bright)CD16- and CD56(dim)CD16(+) subsets), macrophages and dendritic cells (DCs). Furthermore, CD103 expression was analyzed on T cells and their subsets, while PD-1 and PD-L1 expression on all ICs. Cut-off of low and high percent-ages of ICs was determined by the median of variables, and correlation with PFS and OS was calculated. Results. CD3(+) cells were the predominant ICs (median 51%), while the presence of other ICs was much lower (me-dian <= 10%). CD103(+) expression was mostly present on CD8(+), and not CD4(+) cells. PD-1 was mainly expressed on CD3(+) T cells (median 20%), lower expression was observed on other ICs (median <= 10%). PD-L1 expression was not detected. High percentages of CD103(+)CD3(+) T cells, PD-1(+) Tregs, CD56(bright)CD16- NK cells, and DCs correlated with prolonged PFS and OS, while high percentages of CD8(+) cells, macrophages, and PD-1(+)CD56(bright)CD16- NK cells, along with low percentages of CD4(+) cells, correlated with better OS only. DCs were the only independent prognostic marker among all ICs. Conclusions. Our results highlight the potential of ascites tumor-immune microenvironment to provide additional prognostic information for HGSC patients. However, a larger patient cohort and longer follow-up are needed to confirm our findings
引用
收藏
页码:493 / 506
页数:14
相关论文
共 44 条
  • [1] Immune Tumor Microenvironment in Ovarian Cancer Ascites
    Almeida-Nunes, Diana Luisa
    Mendes-Frias, Ana
    Silvestre, Ricardo
    Dinis-Oliveira, Ricardo Jorge
    Ricardo, Sara
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [2] Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer
    Auer, Katharina
    Bachmayr-Heyda, Anna
    Sukhbaatar, Nyamdelger
    Aust, Stefanie
    Schmetterer, Klaus G.
    Meier, Samuel M.
    Gerner, Christopher
    Grimm, Christoph
    Horvat, Reinhard
    Pils, Dietmar
    [J]. ONCOTARGET, 2016, 7 (38) : 61336 - 61354
  • [3] Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer
    Boesmueller, Hans-Christian
    Wagner, Philipp
    Peper, Janet Kerstin
    Schuster, Heiko
    Deborah Lam Pham
    Greif, Karen
    Beschorner, Christine
    Rammensee, Hans-Georg
    Stevanovie, Stefan
    Fend, Falko
    Staebler, Annette
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (04) : 671 - 679
  • [4] Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas?
    Brozic, Andreja
    Marinsek, Ziva Pohar
    Novakovic, Srdjan
    Prevodnik, Veronika Kloboves
    [J]. DIAGNOSTIC PATHOLOGY, 2015, 10
  • [5] The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
    Cai, Jiajing
    Wang, Dongsheng
    Zhang, Guoyuan
    Guo, Xiaolan
    [J]. ONCOTARGETS AND THERAPY, 2019, 12 : 8437 - 8445
  • [6] Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer
    Curiel, TJ
    Cheng, P
    Mottram, P
    Alvarez, X
    Moons, L
    Evdemon-Hogan, M
    Wei, S
    Zou, LH
    Kryczek, I
    Hoyle, G
    Lackner, A
    Carmeliet, P
    Zou, WP
    [J]. CANCER RESEARCH, 2004, 64 (16) : 5535 - 5538
  • [7] Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
    Darb-Esfahani, Silvia
    Kunze, Catarina Alisa
    Kulbe, Hagen
    Sehouli, Jalid
    Wienert, Stephan
    Lindner, Judith
    Budczies, Jan
    Bockmayr, Michael
    Dietel, Manfred
    Denkert, Carsten
    Braicu, Ioana
    Joehrens, Korinna
    [J]. ONCOTARGET, 2016, 7 (02) : 1486 - 1499
  • [8] NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
    Dong, HP
    Elstrand, MB
    Holth, A
    Silins, I
    Berner, A
    Trope, CG
    Davidson, B
    Risberg, B
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 125 (03) : 451 - 458
  • [9] 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
    du Bois, A
    Quinn, M
    Thigpen, T
    Vermorken, J
    Avall-Lundqvist, E
    Bookman, M
    Bowtell, D
    Brady, M
    Casado, A
    Cervantes, A
    Eisenhauer, E
    Friedlaender, M
    Fujiwara, K
    Grenman, S
    Guastalla, JP
    Harper, P
    Hogberg, T
    Kaye, S
    Kitchener, H
    Kristensen, G
    Mannel, R
    Meier, W
    Miller, B
    Neijt, JP
    Oza, A
    Ozols, R
    Parmar, M
    Pecorelli, S
    Pfisterer, J
    Poveda, A
    Provencher, D
    Pujade-Lauraine, E
    Randall, M
    Rochon, J
    Rustin, G
    Sagae, S
    Stehman, F
    Stuart, G
    Trimble, E
    Vasey, P
    Vergote, I
    Verheijen, R
    Wagner, U
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 7 - 12
  • [10] The untapped potential of ascites in ovarian cancer research and treatment
    Ford, Caroline Elizabeth
    Werner, Bonnita
    Hacker, Neville Frederick
    Warton, Kristina
    [J]. BRITISH JOURNAL OF CANCER, 2020, 123 (01) : 9 - 16